Oncology And US Dominate Daiichi's New Mid-Term Plan
Vision Beyond Core ADCs
Major Japanese firm sets targets under a new mid-term plan that envisages the US oncology sector leading growth and revenues, and also casts an eye to novel assets beyond three pillar antibody-drug conjugates and new digital technologies.
You may also be interested in...
Daiichi-Sankyo has received a CHMP positive opinion for use of the antibody-drug conjugate in HER2-positive breast cancer, making this the third major market for the product.
French giant makes its biggest single investment to date in Asia as it prepares to build up regional vaccine production capacity, in part to help prepare for future pandemics.
In this week's podcast version of Five Must-Know Things, hear about whether safety concerns may affect JAK inhibitors, Takeda’s strategic R&D plans, Cigna’s psoriasis insurance program, Phase III readouts to look for, and an overview of the global pharma R&D pipeline.